Facial psoriasis in a mask-like distribution

Zachary, Cameron; Belzer, Annika; Fackler, Nathan; Shiu, Jessica; Smith, Janellen; Ghadially, Ruby

doi:10.1016/j.jdcr.2020.11.013

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the clinical parameters investigated (PASI and Facial PASI) improved with treatment, with a reduction of more than 90% from baseline within 7 days. Improvement was observed in all cases regardless of distribution (peripherofacial or centrofacial 4 , 10 ). The six patients treated had the following distribution: four had overlap between centrofacial and mixed type, and two had peripherofacial (hairline psoriasis).…”

Section: Discussionmentioning

confidence: 82%

Rapid response on facial psoriasis to bimekizumab: case series

Bernardini,

Dattola,

Caldarola

et al. 2024

DIC

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the management of psoriatic lesions in difficult-to-treat areas. In post hoc analysis of phase III trials in plaque psoriasis, bimekizumab has shown safety and complete clearance of high-impact areas. However, these studies did not focus on the effect of bimekizumab on facial lesions. Therefore, this case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.

show abstract

Section: Discussionmentioning

confidence: 82%

Rapid response on facial psoriasis to bimekizumab: case series

Bernardini,

Dattola,

Caldarola

et al. 2024

DIC

View full text Add to dashboard Cite

show abstract

“…Facial psoriasis may be classified into three subtypes: hairline psoriasis or peripherofacial, Sebopsoriasis or centrofacial, and true facial psoriasis or mixed subtype which is the commonest. 6,7 Our case had a mixed subtype with predominant involvement of most of the face albeit in a peculiar distribution which looked like malar rash of systemic lupus erythematosus, however, the same was ruled out following histopathology of the lesion and negative ANA. Vitamin-D analogue like tacalcitol has been used successfully in facial Sebopsoriasis co-existing with scalp involvement.8 Our patient failed a trial of tacalcitol which was given for a period of 3 months in the preceding year.…”

Section: F I G U R E 1 Diffuse Erythematous Scaly Lesions Over Face A...mentioning

confidence: 87%

Successful treatment of recalcitrant facial sebopsoriasis with low‐dose cyclosporine

Mitra

Valarmathi

Kishore

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Dear Editor, Cyclosporine (CysA) is indicated in severe and recalcitrant forms of Psoriasis vulgaris. Existing guidelines recommend starting dose of 3-5 mg/kg/day with gradual tapering. Low-dose CysA has been tried in various studies with better clinical outcomes and side effect profile. 1,2 We herein report a novel indication of low-dose oral CysA in the management of recalcitrant facial sebopsoriasis.A 24-years-old male presented with 4 years history of multiple well-defined itchy scaly lesions over scalp, face, postauricular region, trunk, both the axillae and groin involving 20% body surface area.Skin biopsy performed from the trunk lesion was suggestive of sebopsoriasis. Antinuclear antibody (ANA) and extractable nuclear antibody (ENA) were negative. He had already tried multiple treatments like Siddha, Homeopathy, and Allopathy (topical mid-potent steroids, topical tacrolimus, topical calcipotriol, emollients, and phototherapy), with significant resolution of the body lesions, however, no improvement in the facial lesions. Patient was started on CysA

show abstract

Psoriasis with facial skin lesions that arose against background of withdrawal of ixekizumab (clinical case)

Владимирова

Smirnova

2023

Medicinskij alfavit

View full text Add to dashboard Cite

Facial skin lesions in psoriasis, one of the most common dermatoses, are traditionally considered a relatively rare manifestation of the disease, especially in adult patients, but according to modern data, it is observed in at least 40 % of patients. It is believed that facial skin lesions are more typical for young patients with severe widespread skin lesions, involvement of the nail plates and a protracted course. Localization of rashes on the skin of the face – in a cosmetically and socially significant area – is accompanied by significant impairments in the quality of life of patients. The treatment of facial psoriasis is difficult, and few algorithms have been developed for the management of patients with facial psoriatic lesions. We present a patient with psoriasis involving facial skin that first developed after discontinuation of systemic therapy with an IL-17A inhibitor (ixekizumab). During the follow-up of the patient, it became necessary to re-administer systemic biological therapy with the potential risk of an escape effect. In the article, we discuss the clinical manifestations of facial psoriasis and the impact on the quality of life of patients. A description of the observation of a patient with lesions of the facial skin in severe plaque psoriasis and the role of biological therapy in this direction is presented.

show abstract

Facial psoriasis in a mask-like distribution

Cited by 3 publications

References 10 publications

Rapid response on facial psoriasis to bimekizumab: case series

Rapid response on facial psoriasis to bimekizumab: case series

Successful treatment of recalcitrant facial sebopsoriasis with low‐dose cyclosporine

Psoriasis with facial skin lesions that arose against background of withdrawal of ixekizumab (clinical case)

Contact Info

Product

Resources

About